

# Endometrial Cancer

## Disclaimer

This pathway is for patients with suspected or diagnosed endometrial cancer. See also:

[Heavy Menstrual Bleeding](#)

[Persistent Pelvic Pain](#)

## Contents

Disclaimer .....	1
Red Flags .....	2
<b>Assessment</b> .....	<b>2</b>
Unopposed oestrogen exposure.....	2
<b>Management</b> .....	<b>3</b>
Suspicion of endometrial cancer .....	3
Initial treatment of confirmed endometrial cancer .....	3
Ongoing care and support .....	5
<b>Referral</b> .....	<b>5</b>
<b>Information</b> .....	<b>6</b>
For health professionals.....	6
For patients.....	6

## Red Flags

- [Postmenopausal bleeding](#)

## Assessment

1. History – Check for:
  - [postmenopausal bleeding](#).
  - [intermenstrual bleeding](#).
  - [abnormal vaginal discharge](#), usually watery or blood-tinged.
  - pelvic pain including dyspareunia.
  - unexplained haematuria.
  - unexplained weight loss.
2. Check risk factors for endometrial cancer or hyperplasia. Patients at higher risk are either aged  $\geq 40$  years, or aged  $> 35$  years with one or more of:
  - BMI  $> 35$
  - ***Unopposed oestrogen exposure***

### **Unopposed oestrogen exposure**

- *Chronic anovulation e.g., polycystic ovarian syndrome (PCOS)*
- *Nulliparity, early menarche, late menopause*
- *HRT without progesterone support, including natural or bioidentical hormones (oral or topical)*
- *Tamoxifen or other hormonal treatments of malignancy*
- Family history of endometrial cancer in first degree relative or known Lynch syndrome– see [Familial Cancer Syndromes](#) pathway.

3. Examination:
  - Perform abdominal examination, speculum, and bimanual pelvic examination.
  - Check for inguinal lymphadenopathy.
4. Arrange investigations:
  - FBE, iron studies, liver function tests, and thyroid-stimulating hormone (TSH)
  - Transvaginal pelvic ultrasound (on day 5 or 6 of cycle if premenopausal or on cyclical hormone treatment)
  - Cervical screening test

## Suspicion of endometrial cancer

1. Address the patient's understanding and engagement. Consider **barriers to effective care**.

### **Barriers to effective care**

*Factors that could stop the patient from getting further tests or treatment:*

- *Complexity of cancer care pathway – not knowing when or where to go next*
- *Family, and social network dynamics*
  - *Family history*
  - *Family obligations including dependents*
  - *Work responsibilities*
  - *Community engagement and obligations or responsibilities*
- *Locality and geographical access to health and hospital services*
- *Socio-economic factors, including source of income.*

2. If diagnosis made on ultrasound, refer for gynae-oncology assessment.
3. If normal investigation results, arrange review at 2 months.
  - If appropriate, consider treatment for vaginal atrophy.
  - If symptoms are persisting at 2 months, refer for [urgent or routine gynaecology referral](#).
4. Consider high suspicion of cancer and refer for [urgent or routine gynaecology referral](#) within 2 weeks if:
  - thickened endometrium:
    - Post menopausal (with and without tamoxifen) and an endometrial thickness > 5 mm.
    - Premenopausal early proliferative phase and endometrial thickness > 7 mm.
  - abnormal vaginal bleeding, discharge, or pelvic pain and abnormal clinical examination findings consistent with gynaecological malignancy.
  - evidence of a rapidly growing uterine mass.

## Initial treatment of confirmed endometrial cancer

1. If endometrial cancer is already diagnosed:
  - refer to the **cancer treatment summary letter** from the multidisciplinary disease management team.

### **Cancer treatment summary letter**

*Most importantly should include:*

- *risk of recurrence and intentions of treatment.*
- *goals and quantitative benefit of proposed treatment.*
- *risks of treatment.*
- *what the patient has been told.*

*Usually includes:*

- *diagnostic tests performed and results.*
- *tumour characteristics and other factors determining prognosis.*

- type and date of treatments and a treatment summary.
  - expectations of disease course, including expected discharge from oncology services.
  - interventions and treatment plans from other health professionals.
  - a process for rapid re-entry to specialist medical services for suspected recurrence.
  - a list of symptoms that might need prompt investigation.
  - a list of supportive care services provided and a plan for community care services, including what each service is to provide.
  - contact information for key care providers.
- contact the [GP Liaison Unit](#) for queries about specialist to general practitioner correspondence.

See also [Low-risk Endometrial Cancer Follow-Up](#).

2. If diagnosis made on ultrasound, refer directly to [urgent or routine gynaecology referral](#).

3. Discuss with patient their understanding of treatment options:

- **Treatment options** depend on stage, grade, and co-morbidities.

#### **Treatment options**

- All patients are recommended a hysterectomy and bilateral salpingo-ophorectomy with or without lymph node resection.
  - For most endometrial cancers, laparoscopic procedure is preferred where possible.
  - Other therapies that can be considered through multidisciplinary meeting (MDM) and in discussion with patient include:
    - radiotherapy – external radiation treatment or brachytherapy
    - chemotherapy and cytotoxics
    - hormone therapy – Provera, tamoxifen
  - Fertility-sparing options, if patient is of child-bearing age.
4. Ensure follow-up and surveillance. After initial diagnosis and treatment, the gynaecology service will design an individual follow-up plan according to level of risk of recurrence. The plan may involve regular general practitioner visits, which will detail:
- the frequency of visits.
  - tests required and designated providers.
  - a nominated point-of-contact, if clinical concern.
  - regular assessment of **post-treatment sequelae** and lifestyle behaviours, and appropriate support requests e.g., dietitian, lymphoedema specialist.

#### **Post-treatment sequelae**

Side-effects of radiation or chemotherapy:

- Gastrointestinal sequelae, nausea, vomiting, diarrhoea, rectal bleeding, proctitis, incontinence.
- Hair loss (not carboplatin), skin rashes, mouth ulcers.
- Bladder problems, irritability, incontinence, haematuria.
- General symptoms, fatigue, lethargy, anorexia, mood, and cognition disturbance.
- Easy bruising or bleeding (consider FBE).
- evidence-based advice about a healthy lifestyle.

Patients assessed as having a low risk of recurrence (< 10%) can be solely followed in general practice. See [Low-risk Endometrial Cancer – Follow-up](#).

## Ongoing care and support

1. Provide ongoing care and support:
  - Provide patient with the Cancer Council – [Endometrial Cancer: What to Expect](#) document.
  - See [Cancer Supportive Care](#) for general advice on:
    - lifestyle changes
    - psychological needs
    - financial, legal, and practical needs
    - managing physical sequelae
    - support groups and referral services.
2. For Aboriginal and Torres Strait Islander patients:
  - provide culturally appropriate care.
  - advise the hospital of the patient's Aboriginal and Torres Strait Islander status.
  - ensure follow-up by a culturally appropriate healthcare professional.
3. Consider:
  - referral to palliative care services
  - advance care planning,
  - counselling support,
  - GP Management Plan and Team Care Arrangement,
  - hair loss in cancer therapies.

## Referral

- 1. If diagnosis made on ultrasound, refer for [gynae-oncology assessment](#).
- Refer for [urgent or routine gynaecology referral](#) within 2 weeks if high suspicion of endometrial cancer e.g.:
  - normal investigations, but family history of endometrial cancer in first degree relative or known Lynch syndrome.
  - thickened endometrium:
    - postmenopausal (with and without tamoxifen) and an endometrial thickness > 5 mm.
    - premenopausal early proliferative phase and endometrial thickness > 7 mm.
- abnormal vaginal bleeding, discharge, or pelvic pain and abnormal clinical examination findings consistent with gynaecological malignancy.
- evidence of a rapidly growing uterine mass.
- If normal investigations and symptoms are persisting at 2 month review, refer for [urgent or routine gynaecology referral](#).
- Consider referral to palliative care services or counselling support.

# Information

## For health professionals

### Further information

Cancer Council Australia – [Optimal Cancer Care Pathway for Women with Endometrial Cancer: Quick Reference Guide](#)

## For patients

- Cancer Australia:
  - [Intimacy and Sexuality for Women with Gynaecological Cancer: Starting a Conversation](#)
  - [What are the Risk Factors for Endometrial Cancer?](#)
- Cancer Council:
  - [Cancer of the Uterus](#)
  - [Cancer: What to expect](#)
  - [Endometrial Cancer: What to Expect](#)
- Cancer Council Victoria – [Aboriginal Communities: Information](#)
- National Indigenous Cancer Network – [About Cancer](#)

Last Reviewed: December 2019

[Disclaimer](#)